Literature DB >> 3289601

Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria.

G Edwards1, S Looareesuwan, A J Davies, Y Wattanagoon, R E Phillips, D A Warrell.   

Abstract

1. Chloroquine diphosphate (15 mg base kg-1) was given by constant rate intravenous infusion to two groups of Thai subjects. Eleven were patients with malaria (10 with Plasmodium vivax and one case with Plasmodium malariae) and 10 were healthy normal volunteers. 2. Plasma and packed red-cell concentrations of chloroquine, electrocardiographic intervals, arterial blood pressure and pulse were measured at frequent intervals. 3. Peak plasma concentrations at the end of the infusion ranged from 979 to 2,900 ng ml-1 in the malaria patients. In the group of healthy subjects the range was 550-2,200 ng ml-1. Values for terminal elimination rate constant, (lambda z) plasma clearance (CL), initial volume of distribution (V1) and volume of distribution at steady state (Vss) were calculated. For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05). 4. Chloroquine concentrations in packed red blood cells consistently exceeded those in plasma and showed no consistent change with time throughout the period of study in either group. The median value for the red cell to plasma ratio was between 3 and 4 in each group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3289601      PMCID: PMC1387810          DOI: 10.1111/j.1365-2125.1988.tb03332.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Single intravenous injections of chloroquine in the treatment of falciparum malaria: toxic and immediate therapeutic effects in 110 cases.

Authors:  V SCOTT
Journal:  Am J Trop Med Hyg       Date:  1950-07       Impact factor: 2.345

2.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

3.  Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography.

Authors:  G Alván; L Ekman; B Lindström
Journal:  J Chromatogr       Date:  1982-04-16

4.  Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria.

Authors:  R E Phillips; S Looareesuwan; N J White; K Silamut; S Kietinun; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

5.  Cardiovascular toxicity and distribution kinetics of intravenous chloroquine.

Authors:  S Looareesuwan; N J White; P Chanthavanich; G Edwards; D D Nicholl; C Bunch; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

6.  Parenteral chloroquine for treating falciparum malaria.

Authors:  N J White; G Watt; Y Bergqvist; E K Njelesani
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

7.  Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria.

Authors:  O Walker; A H Dawodu; A A Adeyokunnu; L A Salako; G Alvan
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Disposition of chloroquine in man after single intravenous and oral doses.

Authors:  L L Gustafsson; O Walker; G Alván; B Beermann; F Estevez; L Gleisner; B Lindström; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

9.  Kinetics of the uptake and elimination of chloroquine in children with malaria.

Authors:  S A Adelusi; A H Dawodu; L A Salako
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

10.  Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria.

Authors:  N J White; S Looareesuwan; D A Warrell; M J Warrell; D Bunnag; T Harinasuta
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

View more
  22 in total

1.  Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.

Authors:  Fabian Müller; Jörg König; Hartmut Glaeser; Ingrid Schmidt; Oliver Zolk; Martin F Fromm; Renke Maas
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.

Authors:  Brioni R Moore; Madhu Page-Sharp; Jillian R Stoney; Kenneth F Ilett; Jeffrey D Jago; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

4.  Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.

Authors:  John M Benjamin; Brioni R Moore; Sam Salman; Madhu Page-Sharp; Somoyang Tawat; Gumal Yadi; Lina Lorry; Peter M Siba; Kevin T Batty; Leanne J Robinson; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

5.  Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

6.  Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.

Authors:  Hyeong-Seok Lim; Jeong-Soo Im; Joo-Youn Cho; Kyun-Seop Bae; Terry A Klein; Joon-Sup Yeom; Tae-Seon Kim; Jae-Seon Choi; In-Jin Jang; Jae-Won Park
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

7.  Enhancement of drug susceptibility in Plasmodium falciparum in vitro and Plasmodium berghei in vivo by mixed-function oxidase inhibitors.

Authors:  A M Ndifor; R E Howells; P G Bray; J L Ngu; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication.

Authors:  Claudia Bönsch; Christoph Kempf; Ivo Mueller; Laurens Manning; Moses Laman; Timothy M E Davis; Carlos Ros
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

9.  Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells.

Authors:  D Ghigo; E Aldieri; R Todde; C Costamagna; G Garbarino; G Pescarmona; A Bosia
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

10.  Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.

Authors:  Harin A Karunajeewa; Kenneth F Ilett; Ivo Mueller; Peter Siba; Irwin Law; Madhu Page-Sharp; Enmoore Lin; Jovitha Lammey; Kevin T Batty; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.